Amyloid β-Peptide (1-42) human

Amyloid β-Peptide (1-42) human is a synthetic peptide corresponding to the 1-42 amino acid sequence of the human amyloid beta protein, a fragment derived from the amyloid precursor protein (APP) through enzymatic cleavage. Its high propensity to aggregate and form fibrillar structures has established it as a central molecule in neurodegenerative research, particularly in the context of protein misfolding and amyloidogenesis. As a result, this peptide serves as a critical biochemical tool for elucidating the molecular mechanisms underlying protein aggregation, synaptic dysfunction, and cellular toxicity in neuronal systems.

Neurodegeneration research: As a key component in the study of Alzheimer's disease pathology, Amyloid β (1-42) is widely utilized to model amyloid plaque formation in vitro and in vivo. Its tendency to self-assemble into oligomers and fibrils closely mimics the aggregation process observed in affected brain tissue, enabling researchers to investigate the initiation and progression of amyloidogenic cascades. This application supports the identification of critical molecular events and cellular responses associated with neurodegenerative disorders.

Protein aggregation studies: The peptide is extensively employed in biophysical and biochemical assays aimed at characterizing the kinetics and structural transitions of amyloid fibril formation. Researchers leverage its well-defined sequence to analyze nucleation, elongation, and maturation phases of aggregation using techniques such as thioflavin T fluorescence, electron microscopy, and atomic force microscopy. These studies provide quantitative and qualitative insights into the physicochemical properties of amyloid assemblies, facilitating the development of aggregation modulators and inhibitors.

High-throughput screening: In drug discovery and compound screening workflows, Amyloid β (1-42) serves as a robust substrate for evaluating the efficacy of small molecules, peptides, and biologics in modulating amyloid aggregation. By incorporating the peptide into cell-free or cell-based assay systems, researchers can rapidly assess candidate compounds for their ability to alter aggregation kinetics, disrupt oligomerization, or prevent fibril formation. This approach accelerates the identification and optimization of novel anti-amyloid agents.

Cellular toxicity assays: The peptide's neurotoxic properties are exploited in cellular models to probe mechanisms of amyloid-induced toxicity, synaptic impairment, and neuronal cell death. By exposing cultured neurons or glial cells to aggregated or oligomeric forms, investigators can dissect downstream signaling events, oxidative stress responses, and apoptotic pathways. These experiments are instrumental in delineating the cellular consequences of amyloid pathology and in validating potential neuroprotective strategies.

Biomarker and diagnostic tool development: Amyloid β (1-42) is also utilized in the development and validation of analytical platforms for the detection and quantification of amyloid species in biological samples. Its defined sequence and aggregation characteristics make it an ideal standard or target for immunoassays, biosensors, and mass spectrometry-based methods. These applications support the advancement of sensitive and specific diagnostic tools for research use in neurodegenerative disease models and biomarker discovery.

1. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors

2. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

3. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

4. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

5. High fat diet and GLP-1 drugs induce pancreatic injury in mice